

This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|---------------------------|---------------------------|---|---|---|
| Ophthalmic disease | | | | |
| Ophthalmic; dental | Cyclin M4 (CNNM4) | <p>Genomewide haplotype analysis identified mutations in <i>CNNM4</i> that could be targeted to help treat cone-rod dystrophy associated with amelogenesis imperfecta. Single-nucleotide haplotype analysis and genetic mapping of individuals affected by the ophthalmic and dental syndrome from three families showed mutations in <i>CNNM4</i>. In mice, immunohistochemistry studies showed that <i>Cnnm4</i> is localized to the cell body of ameloblasts in the tooth and to various cells of the eye. Next steps could include testing viral-mediated gene replacement of <i>CNNM4</i> to treat the syndrome.</p> <p><i>SciBX</i> 2(8); doi:10.1038/scibx.2009.334 Published online Feb. 26, 2009</p> | Patent and licensing status unavailable | <p>Polok, B. <i>et al. Am. J. Hum. Genet.</i>; published online Feb. 13, 2009; doi:10.1016/j.ajhg.2009.01.006 Contact: Daniel F. Schorderet, IRO—Institute of Ophthalmology Research, Sion, Switzerland e-mail: daniel.schorderet@irovision.ch</p> |